Assenagon Asset Management S.A. Trims Position in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)

Assenagon Asset Management S.A. cut its position in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) by 66.3% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 143,806 shares of the biotechnology company's stock after selling 282,755 shares during the quarter. Assenagon Asset Management S.A. owned approximately 0.68% of Enanta Pharmaceuticals worth $1,490,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in ENTA. State Board of Administration of Florida Retirement System acquired a new position in Enanta Pharmaceuticals in the first quarter valued at $118,000. Vanguard Group Inc. lifted its position in Enanta Pharmaceuticals by 7.5% during the 1st quarter. Vanguard Group Inc. now owns 1,928,078 shares of the biotechnology company's stock worth $33,664,000 after acquiring an additional 134,292 shares during the period. Acadian Asset Management LLC grew its stake in shares of Enanta Pharmaceuticals by 1.3% in the 1st quarter. Acadian Asset Management LLC now owns 853,896 shares of the biotechnology company's stock valued at $14,906,000 after purchasing an additional 10,952 shares during the last quarter. Virtu Financial LLC purchased a new stake in shares of Enanta Pharmaceuticals during the first quarter worth approximately $191,000. Finally, Farallon Capital Management LLC lifted its holdings in shares of Enanta Pharmaceuticals by 3.5% during the first quarter. Farallon Capital Management LLC now owns 2,095,000 shares of the biotechnology company's stock worth $36,579,000 after purchasing an additional 70,000 shares during the period. Hedge funds and other institutional investors own 94.99% of the company's stock.

Enanta Pharmaceuticals Stock Performance

ENTA stock traded down $0.29 during midday trading on Friday, hitting $10.95. 100,080 shares of the stock were exchanged, compared to its average volume of 201,727. The stock's 50-day moving average price is $11.73 and its 200-day moving average price is $12.72. The stock has a market cap of $232.03 million, a price-to-earnings ratio of -2.01 and a beta of 0.58. Enanta Pharmaceuticals, Inc. has a fifty-two week low of $8.08 and a fifty-two week high of $17.80.

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) last released its quarterly earnings results on Monday, August 5th. The biotechnology company reported ($1.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.43) by $0.36. Enanta Pharmaceuticals had a negative return on equity of 63.75% and a negative net margin of 160.27%. The business had revenue of $17.97 million during the quarter, compared to the consensus estimate of $17.44 million. The business's revenue was down 4.9% on a year-over-year basis. During the same quarter in the previous year, the company posted ($1.27) EPS. Research analysts anticipate that Enanta Pharmaceuticals, Inc. will post -5.3 EPS for the current year.

Analysts Set New Price Targets

ENTA has been the subject of several recent analyst reports. JMP Securities restated a "market outperform" rating and issued a $22.00 target price on shares of Enanta Pharmaceuticals in a research note on Wednesday, October 9th. HC Wainwright reissued a "buy" rating and issued a $27.00 price target on shares of Enanta Pharmaceuticals in a report on Thursday, October 10th. JPMorgan Chase & Co. dropped their price objective on Enanta Pharmaceuticals from $11.00 to $10.00 and set an "underweight" rating on the stock in a report on Tuesday, August 6th. Finally, Evercore ISI upgraded shares of Enanta Pharmaceuticals to a "strong-buy" rating in a research report on Tuesday, August 6th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Enanta Pharmaceuticals has a consensus rating of "Moderate Buy" and an average target price of $20.00.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.